The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial
Open accessAbstract
Lamivudine is effective to control hepatitis B virus (HBV) reactivation in HBV-carrying cancer patients who undergo chemotherapy, but the optimal treatment protocol remains undetermined. In this study, HBV carriers with newly diagnosed non-Hodgkin's lymphoma (NHL) who underwent chemotherapy were randomized to either prophylactic (P) or therapeutic (T) lamivudine treatment groups. Group P patients started lamivudine from day 1 of the first course of chemotherapy and continued treatment until 2 months after completion of chemotherapy. Group T patients received chemotherapy alone and started lamivudine treatment only if serum alanine aminotransferase (ALT) levels elevated to greater than 1.5-fold of the upper normal limit (ULN). The primary endpoint was incidence of HBV reactivation during the 12 months after starting chemotherapy. During chemotherapy, fewer group P patients had HBV reactivation (11.5% versus 56%, P = 0.001), HBV-related hepatitis (7.7% versus 48%, P = 0.001), or severe hepatitis (ALT more than 10-fold ULN) (0 versus 36%, P < 0.001). No hepatitis-related deaths occurred during protocol treatment. Prophylactic lamivudine use was the only independent predictor of HBV reactivation. After completion of chemotherapy, the incidence of HBV reactivation did not differ between the 2 groups. Two patients, both in group P, died of HBV reactivation–related hepatitis, 173 and 182 days, respectively, after completion of protocol treatment. When compared with an equivalent group of lamivudine-naïve lymphoma patients who underwent chemotherapy, therapeutic use of lamivudine neither reduced the severity of HBV-related hepatitis nor changed the patterns of HBV reactivation. Conclusion: Prophylactic lamivudine use, but not therapeutic use, reduces the incidence and severity of chemotherapy-related HBV reactivation in NHL patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
A One-Year Trial of Lamivudine for Chronic Hepatitis B
Lai, C.-L., Chien, R.-N., Leung, N. W. Y., Chang, T.-T., Guan, R., Tai, D.-I., Ng, K.-Y., Wu, P.-C., Dent, J. C., Barber, J., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807093390201 · Cited by 1,754
Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy
Lok, A. S. F., Liang, R. H. S., Chiu, E. K. W., Wong, K.-L., Chan, T.-K., & Todd, D. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90599-g · Cited by 827
A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection
Dienstag, J. L., Perrillo, R. P., Schiff, E. R., Bartholomew, M., Vicary, C., & Rubin, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332501 · Cited by 800
Lok, A. S. F., & McMahon, B. J. (2001) · Hepatology · doi:10.1053/jhep.2001.29401 · Cited by 709
Yeo, W., Chan, P. K. S., Zhong, S., Ho, W. M., Steinberg, J. L., Tam, J. S., Hui, P., Leung, N. W. Y., Zee, B., & Johnson, P. J. (2000) · Journal of Medical Virology · doi:10.1002/1096-9071(200011)62:3<299::aid-jmv1>3.0.co;2-0 · Cited by 627
Chronic hepatitis B: Update of recommendations† ‡
Lok, A. S. F., & McMahon, B. J. (2004) · Hepatology · doi:10.1002/hep.20110 · Cited by 500
Lau, G. K. K., Yiu, H. H. Y., Fong, D. Y. T., Cheng, H.-C., Au, W.-Y., Lai, L. S. F., Cheung, M., Zhang, H.-Y., Lie, A., Ngan, R., et al. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.026 · Cited by 458
Yeo, W., Zee, B., Zhong, S., Chan, P. K. S., Wong, W.-L., Ho, W. M., Lam, K. C., & Johnson, P. J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601699 · Cited by 312
Cheng, A., Hsiung, C. A., Su, I., Chen, P., Chang, M., Tsao, C.-J., Kao, W.-Y., Uen, W., Hsu, C., Tien, H., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50220 · Cited by 289
Self-citationYeo, W., Chan, P. K. S., Ho, W. M., Zee, B. C.-Y., Lam, K. C., Lei, K. I. K., Chan, A. T. �., Mok, T. S. K., Lee, J. J., Leung, T. W. H., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.161 · Cited by 259
Yeh, S.-H., Tsai, C.-Y., Kao, J.-H., Liu, C.-J., Kuo, T.-J., Lin, M.-W., Huang, W.-L., Lu, S.-F., Jih, J., Chen, D.-S., et al. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.06.031 · Cited by 206
Self-citationA randomized controlled trial of lamivudine to treat acute hepatitis B
Kumar, M., Satapathy, S., Monga, R., Das, K., Hissar, S., Pande, C., Sharma, B. C., & Sarin, S. K. (2007) · Hepatology · doi:10.1002/hep.21486 · Cited by 206
Kohrt, H. E. K., Ouyang, D. L., & Keeffe, E. B. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03081.x · Cited by 123
Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy
Yeo, W., Steinberg, J., Tam, J. S., Chan, P. K. S., Leung, N. W. Y., Lam, K. C., Mok, T. S. K., & Johnson, P. J. (1999) · Journal of Medical Virology · Cited by 107
Liao, C., Lee, C., Wu, H., Wang, M., Lu, S., & Eng, H. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03239.x · Cited by 89
Self-citation
Cited by
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39480 · Cited by 2,777
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Self-citation
Metadata
- Authors
- Hsu, C., Hsiung, C. A., Su, I.-J., Hwang, W.-S., Wang, M.-C., Lin, S.-F., Lin, T.-H., Hsiao, H.-H., Young, J.-H., Chang, M.-C., Liao, Y.-M., Li, C.-C., Wu, H.-B., Tien, H.-F., Chao, T.-Y., Liu, T.-W., Cheng, A.-L., & Chen, P.-J.
- Venue
- Hepatology
- Published
- 2008-03
- Volume
- 47
- Issue
- 3
- Pages
- 844-853
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2164785014
- Cited by
- 305
- References
- 18
- FWCI
- 15.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.